戻る Agenda
Session 4: HTA, Pricing & Reimbursement challenges for ATMPs
Session Chair(s)
Alexander Natz, JD
Secretary General
European Confederation of Pharmaceutical Entrepreneurs, Belgium
How to make sure ATMPS reach patients in Europe? Exchange with experts for concrete solutions to ensure equal access to these transformative therapies! Can innovative pricing models address payer’s uncertainties? Will authorities finally adapt HTA process to the specificities of ATMPs? What does the EU Pharma Strategy imply for ATMPs?
Join us in this session to discuss with experts and fellow stakeholders.
Topics explored in this Session:
- Innovative pricing models as a tool to address uncertainties.
- Implications of the Pharma Strategy on ATMPs.
- HTAs and Payers preparedness for ATMPs.
- Cross-border healthcare and advice harmonisation between Member States.
Speaker(s)
Implications of the Pharma Strategy on ATMPs – EU Perspective
Paolo Morgese, MSC
Alliance for Regenerative Medicine (ARM), Belgium
Head of Public Affairs
Innovative pricing models as a tool to address uncertainties – German perspective
Alexander Natz, JD
European Confederation of Pharmaceutical Entrepreneurs, Belgium
Secretary General
HTA, pricing & Reimbursement approach for ATMPs - UK perspective
Christian Hill
MAP Biopharma Limited, United Kingdom
Chief Executive Officer